Black Diamond Therapeutics Presents Promising BDTX-1535

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Black Diamond ,Arizona ,United States ,American ,Patrick Wen ,Nader Sanai ,Mario Corso ,International Conference On Molecular ,Nasdaq ,Ivy Brain Tumor Center ,Diamond Therapeutics Inc ,Company Masterkey ,American Society Of Clinical Oncology ,Oncology At Dana Farber Cancer Institute ,Exchange Commission ,Diamond Therapeutics ,American Society ,Clinical Oncology ,Dana Farber Cancer ,Generation Covalent ,Recurrent Glioblastoma ,Dose Escalation Results ,Molecular Targets ,Trigger Trial ,Recurrent High Grade Glioma ,Ivy Brain Tumor ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,Investor Relations ,